ACADIA Pharmaceuticals(ACAD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACAD ACADIA Pharmaceuticals

Market Closed 09-11 16:00:00 EDT

27.83

+0.09

+0.32%

盘后27.75

-0.08-0.29%

19:34 EDT

High28.24	Low27.74	Vol1.17M
Open27.98	D1 Closing27.74	Amplitude1.80%
Mkt Cap4.80B	Tradable Cap3.58B	Total Shares172.31M
T/O32.71M	T/O Rate0.91%	Tradable Shares128.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACAD","market":"US","secType":"STK","nameCN":"ACADIA Pharmaceuticals","latestPrice":27.83,"timestamp":1789156800000,"preClose":27.74,"halted":0,"volume":1172902,"hourTrading":{"tag":"盘后","latestPrice":27.7502,"preClose":27.83,"latestTime":"19:34 EDT","volume":62110,"amount":1728474.3946,"timestamp":1789169656715,"change":-0.0798,"changeRate":-0.002867,"amplitude":0.002867},"delay":0,"changeRate":0.0032444124008651717,"floatShares":128722546,"shares":172305518,"eps":2.195511,"marketStatus":"Market Closed","change":0.09,"latestTime":"09-11 16:00:00 EDT","open":27.98,"high":28.24,"low":27.74,"amount":32709320.945628,"amplitude":0.018025,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.195511,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":27.74,"preHourTrading":{"tag":"盘前","latestPrice":27.96,"preClose":27.74,"latestTime":"09:29 EDT","volume":2842,"amount":79405.98587599999,"timestamp":1789133399999,"change":0.22,"changeRate":0.007931,"amplitude":0.016583},"postHourTrading":{"tag":"盘后","latestPrice":27.7502,"preClose":27.83,"latestTime":"19:34 EDT","volume":62110,"amount":1728474.3946,"timestamp":1789169656715,"change":-0.0798,"changeRate":-0.002867,"amplitude":0.002867},"volumeRatio":0.8035110819067238,"impliedVol":1.3704,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/ACAD/wiki","defaultTab":"wiki","newsList":[{"id":"2666057284","title":"Acadia Pharmaceuticals - on Aug 24, Court Preliminarily Approves Settlement of Kanner Et Al. V. Biggar Et Al. Derivative Action - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2666057284","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666057284?lang=en_us&edition=fundamental","pubTime":"2026-09-12 05:18","pubTimestamp":1789161499,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530GK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU2065169927.USD","ACAD","LU2065171311.SGD","LU2065171402.SGD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664876768","title":"Canaccord Genuity Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664876768","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664876768?lang=en_us&edition=fundamental","pubTime":"2026-09-03 18:56","pubTimestamp":1788433018,"startTime":"0","endTime":"0","summary":"In a report released today, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on ACADIA Pharmaceuticals, with a price target of $36.00...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-acadia-pharmaceuticals-acad-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-acadia-pharmaceuticals-acad-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662914732","title":"ACADIA Pharmaceuticals (ACAD) Gets a Buy from Deutsche Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2662914732","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662914732?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:36","pubTimestamp":1787661418,"startTime":"0","endTime":"0","summary":"In a report released today, David Hoang from Deutsche Bank maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $38.00. Hoang ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/acadia-pharmaceuticals-acad-gets-a-buy-from-deutsche-bank-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/acadia-pharmaceuticals-acad-gets-a-buy-from-deutsche-bank-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065171311.SGD","LU2065170008.USD","BK4588","BK4552","BK4118","ACAD","BK4585","LU2065171402.SGD","BK4566","LU2065169927.USD","DB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662731698","title":"Deutsche Bank Adjusts ACADIA Pharmaceuticals PT to $38 From $37, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2662731698","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662731698?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:43","pubTimestamp":1787658203,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $33.85, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DB","ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662781491","title":"U.S. Research Roundup-Masco, Sherwin-Williams, Vulcan Materials","url":"https://stock-news.laohu8.com/highlight/detail?id=2662781491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662781491?lang=en_us&edition=fundamental","pubTime":"2026-08-25 15:27","pubTimestamp":1787642845,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Masco, Sherwin-Williams, Vulcan MaterialsAug 25 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Masco","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL8N44M0AY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BKR","ACM","FAC","MAS","IETC","PTF","ANAB","BXP","FBIN","SMHX","WMS","FMC","DAMD","FLNC","CSL","GPN","AMAT","CLSE","KDK","AWI","AMRZ","ALB","DNLI","SHW","DT","JBTM","KRO","CHYM","APMD","AMD","FIS","LRCX","EMSF","TEK","MLM","HON","INSM","CLMT","GTLB","MU","VMC","ACAD","EXP","LEU","MRSH","MRVL","GTEK","KNF","FIVE","CURB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661220803","title":"Acadia Pharmaceuticals Gets European Approval of Rett Syndrome Drug Daybu","url":"https://stock-news.laohu8.com/highlight/detail?id=2661220803","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661220803?lang=en_us&edition=fundamental","pubTime":"2026-08-24 18:06","pubTimestamp":1787565960,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals has won European Commission approval for its Daybu as a treatment for neurobehavioral symptoms of Rett syndrome in patients five and older.Acadia on Monday said the green light makes Daybu the first and only treatment approved in the European Union for Rett syndrome, a rare neurodevelopmental disorder.The San Diego drugmaker said it will now begin pricing and reimbursement negotiations with relevant national authorities across the EU.Acadia, which markets Daybu as Daybue in the U.S. and Canada, earlier this month said it expects global net product sales of the drug to reach $480 million to $510 million this year.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD","LU2065170008.USD","BK4139","BK4231","AKR","EPV","LU2065171402.SGD","LU2065171311.SGD","BK4080","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661226855","title":"EU Approves Acadia’s DAYBU for Rett Syndrome Symptoms in Patients 5 and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=2661226855","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661226855?lang=en_us&edition=fundamental","pubTime":"2026-08-24 15:01","pubTimestamp":1787554888,"startTime":"0","endTime":"0","summary":"EU approves Acadia’s DAYBU for Rett syndrome symptoms in patients 5 and olderEuropean Commission granted marketing authorization for Acadia’s DAYBU (trofinetide) in the EU for Rett syndrome neurobehav","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL2fJSFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","BK4139","LU2065170008.USD","ACAD","LU2065169927.USD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661887226","title":"European Commission Approves Daybu® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union","url":"https://stock-news.laohu8.com/highlight/detail?id=2661887226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661887226?lang=en_us&edition=fundamental","pubTime":"2026-08-24 15:01","pubTimestamp":1787554860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA8QGNSN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065170008.USD","ACAD","BK4139","LU2065171311.SGD","LU2065169927.USD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661226881","title":"Acadia Pharmaceuticals - Receives Ec Marketing Authorization for Daybu for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2661226881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661226881?lang=en_us&edition=fundamental","pubTime":"2026-08-24 15:01","pubTimestamp":1787554860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA8QGNSN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACAD","LU2065171311.SGD","LU2065170008.USD","BK4139","LU2065169927.USD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660464925","title":"Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Insmed (INSM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660464925","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660464925?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:40","pubTimestamp":1787053239,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ACADIA Pharmaceuticals (ACAD), Insmed (INSM) and Mer...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-acadia-pharmaceuticals-acad-insmed-insm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-acadia-pharmaceuticals-acad-insmed-insm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU2065171311.SGD","LU0053671581.USD","LU2065170008.USD","ACAD","LU0889565916.HKD","INSM","LU0320765992.SGD","LU0109394709.USD","LU2065169927.USD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660452583","title":"Stronger 2026 Outlook After Mixed Q2 Results Might Change The Case For Investing In ACAD (ACAD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660452583","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660452583?lang=en_us&edition=fundamental","pubTime":"2026-08-18 13:17","pubTimestamp":1787030248,"startTime":"0","endTime":"0","summary":"In August 2026, ACADIA Pharmaceuticals Inc. reported past second-quarter 2026 results showing revenue of US$307.96 million and net income of US$31.5 million, with earnings per share from continuing operations of US$0.18, alongside higher year-to-date revenue but lower net income compared with the same period in 2025.\nOn the same day, the company raised its full-year 2026 guidance, lifting projected total revenues to US$1.24–US$1.30 billion and increasing expected DAYBUE global net product...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/stronger-2026-outlook-after-mixed-q2-results-might-change-th","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/stronger-2026-outlook-after-mixed-q2-results-might-change-th","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065169927.USD","LU2065170008.USD","LU2065171311.SGD","ACAD","BK4139","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660762438","title":"UBS Adjusts Price Target on ACADIA Pharmaceuticals to $49 From $45, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2660762438","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660762438?lang=en_us&edition=fundamental","pubTime":"2026-08-17 21:39","pubTimestamp":1786973960,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $33.85, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658927217","title":"Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and ACADIA Pharmaceuticals (ACAD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658927217","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658927217?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:10","pubTimestamp":1786522207,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Elanco Animal Health (ELAN) and ACADIA Pharmaceutica...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-elanco-animal-health-elan-and-acadia-pharmaceuticals-acad-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-elanco-animal-health-elan-and-acadia-pharmaceuticals-acad-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1941712264.USD","LU2065171402.SGD","BK4007","BK4139","LU1941712348.USD","LU2065171311.SGD","HCSG","LU2065170008.USD","ELAN","ACAD","BK4585","BK4581","LU0029874061.USD","BK4137","LU2065169927.USD","BK4561","XLV","BK4588","XBI","LU0128526141.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658092270","title":"Acadia Pharmaceuticals Inc. : Needham Raises Target Price to $41 from $38","url":"https://stock-news.laohu8.com/highlight/detail?id=2658092270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658092270?lang=en_us&edition=fundamental","pubTime":"2026-08-12 15:54","pubTimestamp":1786521287,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065169927.USD","LU2065171311.SGD","LU2065171402.SGD","LU2065170008.USD","ACAD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658593849","title":"Immunic Appoints Elena Ridloff to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2658593849","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658593849?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:07","pubTimestamp":1786392440,"startTime":"0","endTime":"0","summary":"Immunic appoints Elena Ridloff to board of directorsImmunic appointed Elena Ridloff to its board, effective Aug. 6, 2026.Ridloff is CFO at Sionna Therapeutics.She previously served as EVP and CFO at A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL8Qq8r4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1078025761.USD","IMUX","LU0310800379.SGD","LU0029864427.USD","LU0289739699.SGD","LU2089284900.SGD","LU0792757196.USD","LU0827474353.SGD","LU1301847155.USD","LU1989771016.USD","LU0976567544.SGD","LU2237443465.HKD","LU0266013472.USD","LU0969580561.USD","LU0920783379.SGD","AZN.UK","LU0128525689.USD","LU0997586432.USD","LU0757432116.USD","LU2065171402.SGD","IE00B4R5TH58.HKD","KYMR","LU0211327993.USD","LU2112291526.USD","LU2324357040.USD","SGXZ57979304.SGD","BK5011","LU0128525929.USD","LU0889566641.SGD","LU1153585028.USD","LU1863844749.USD","ACAD","LU2065171311.SGD","LU2237443978.SGD","LU0882574055.USD","LU1989772923.USD","LU0203347892.USD","LU1496350171.SGD","LU1267930813.SGD","LU1170363599.USD","LU2133065610.SGD","LU0047473722.EUR","LU1019632923.USD","LU0857590862.USD","LU1064927863.SGD","LU0432979614.USD","LU0203345920.USD","03165","LU2237443549.SGD","LU0887340254.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658552930","title":"Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2658552930","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658552930?lang=en_us&edition=fundamental","pubTime":"2026-08-10 23:33","pubTimestamp":1786376001,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals (ACAD) could benefit from wider Daybue use, steady Nuplazid growth, higher cash flow and a strong balance sheet, but upcoming Remlifanserin trial data and the stock's valuation ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU2065169927.USD","AKR","BK4080","ACAD","LU2065171311.SGD","LU2065171402.SGD","BK4231","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658938592","title":"ACADIA Pharmaceuticals (ACAD) Gets a Buy from Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2658938592","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658938592?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:55","pubTimestamp":1786359351,"startTime":"0","endTime":"0","summary":"In a report released today, Yigal Nochomovitz from Citi maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $39.00. Nochomovi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/acadia-pharmaceuticals-acad-gets-a-buy-from-citi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/acadia-pharmaceuticals-acad-gets-a-buy-from-citi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065169927.USD","LU2065171402.SGD","LU2065170008.USD","BK4139","LU2065171311.SGD","ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658984676","title":"Morgan Stanley Adjusts PT on ACADIA Pharmaceuticals to $27 From $26, Maintains Equalweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2658984676","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658984676?lang=en_us&edition=fundamental","pubTime":"2026-08-10 17:25","pubTimestamp":1786353931,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $33.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657621571","title":"Acadia Pharmaceuticals CFO Mark C. Schneyer Disposes of 25,141 Common Shares Worth $730,047.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2657621571","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657621571?lang=en_us&edition=fundamental","pubTime":"2026-08-08 06:00","pubTimestamp":1786140051,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals CFO Mark C. Schneyer disposes of 25,141 common shares worth $730,047.52ACADIA Pharmaceuticals CFO Mark C. Schneyer cut his stake to 67,828 shares in transactions dated Aug. 5-6.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL3tGtZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Acadia Pharmaceuticals CFO Mark C. Schneyer Disposes of 25,141 Common Shares Worth $730,047.52","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2065169927.USD","ACAD","LU2065171311.SGD","LU2065171402.SGD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657577268","title":"ACADIA Pharmaceuticals (ACAD) Stock Jumps As Valuation Gap Draws Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2657577268","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657577268?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:37","pubTimestamp":1785973065,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals stock jumped 6.1% to US$28.80 after earnings, capping a strong run over the past three months. The move lines up with what the numbers signal. Q2 2026 revenue reached US$307.96 million and net income was US$31.5 million, keeping ACADIA on a solid profitability footing. Yet the real story for anyone thinking beyond this quarter is how that improving earnings base sits against a P/E of 13 and a discounted cash flow estimate of US$87.67 per share. The short term is...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/acadia-pharmaceuticals-acad-stock-jumps-as-valuation-gap-dra","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/acadia-pharmaceuticals-acad-stock-jumps-as-valuation-gap-dra","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DECU","ACAD","RGLO","GXDW","LU2065171311.SGD","FEBU","LU2065170008.USD","PMDE","VOTE","LU2065171402.SGD","VGFPF","LU2065169927.USD","JOYT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acadia.com","stockEarnings":[{"period":"1week","weight":-0.0068},{"period":"1month","weight":-0.055},{"period":"3month","weight":0.3196},{"period":"6month","weight":0.3503},{"period":"1year","weight":0.15},{"period":"ytd","weight":0.0419}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.058102},{"month":2,"riseRate":0.636364,"avgChangeRate":0.023325},{"month":3,"riseRate":0.409091,"avgChangeRate":0.049753},{"month":4,"riseRate":0.454545,"avgChangeRate":0.00093},{"month":5,"riseRate":0.545455,"avgChangeRate":0.056897},{"month":6,"riseRate":0.521739,"avgChangeRate":-0.007217},{"month":7,"riseRate":0.608696,"avgChangeRate":0.051329},{"month":8,"riseRate":0.565217,"avgChangeRate":0.019184},{"month":9,"riseRate":0.478261,"avgChangeRate":0.021317},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.024848},{"month":11,"riseRate":0.454545,"avgChangeRate":0.031974},{"month":12,"riseRate":0.545455,"avgChangeRate":0.059204}],"exchange":"NASDAQ","name":"ACADIA Pharmaceuticals","nameEN":"ACADIA Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ACADIA Pharmaceuticals(ACAD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ACADIA Pharmaceuticals(ACAD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ACADIA Pharmaceuticals,ACAD,ACADIA Pharmaceuticals股票,ACADIA Pharmaceuticals股票老虎,ACADIA Pharmaceuticals股票老虎国际,ACADIA Pharmaceuticals行情,ACADIA Pharmaceuticals股票行情,ACADIA Pharmaceuticals股价,ACADIA Pharmaceuticals股市,ACADIA Pharmaceuticals股票价格,ACADIA Pharmaceuticals股票交易,ACADIA Pharmaceuticals股票购买,ACADIA Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ACADIA Pharmaceuticals(ACAD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ACADIA Pharmaceuticals(ACAD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}